Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clostridium butyricum + bifidobacterium
- Development stage
- Unknown
- Lead developer
- Shenzhen Kexing Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Clostridium butyricum + Bifidobacterium is a combination probiotic product containing live strains of the anaerobic, spore-forming bacterium Clostridium butyricum and species from the Bifidobacterium genus (often B. infantis or other clinically used strains). This combination is designed to restore and maintain healthy intestinal flora, particularly after disruption by antibiotics or infections. The mechanism of action involves modulation of gut microbiota composition, enhancement of short-chain fatty acid (butyrate) production (by C. butyricum), anti-inflammatory effects through cytokine regulation (e.g., normalization of IL-10, IFN-γ, TNF-α), improvement in intestinal barrier function, and attenuation of systemic inflammation. Clinical studies have shown that this combination can be more effective than single-strain probiotics for conditions such as antibiotic-associated diarrhea (AAD) and may also benefit chronic stress-induced gut alterations via Nrf2 pathway activation[1][3][5]. It is available in various formulations including sachets and capsules.
- Brand names
- Gutcare
- Other names
- clostridium butyricum combined with bifidobacteriumclostridium butyricum + bifidobacterium infantisprobiotic mixture of clostridium butyricum and bifidobacterium
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on clostridium butyricum + bifidobacterium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clostridium butyricum + bifidobacterium.